CTT Pharmaceutical Reports U.S. Patent Approval for Micelle Delivery Tech

What Happened

• CTT Pharmaceutical Holdings, Inc. (OTCQB: CTTH) announced in an 8-K (Item 8.01) that the U.S. Patent Office granted a continuation‑in‑part (CIP) patent for the company’s micelle delivery technology. The patent was issued a patent number and became effective August 11, 2026. The filing notes the patent specifically covers formulations involving nicotine, vitamins, and caffeine and their use in several oral delivery formats.

Key Details

• Patent type: continuation‑in‑part (CIP) approved by the United States Patent Office.
• Effective date: August 11, 2026; a patent number was issued (not specified in the 8‑K text).
• Scope: expressly covers nicotine, vitamins, and caffeine.
• Permitted product formats listed: dissolvable strips, gum, pouches, lozenges, and dissolving tablets.

Why It Matters

• The new U.S. patent strengthens CTT’s intellectual property position for its micelle delivery platform in products that deliver nicotine, vitamins, and caffeine via oral formats. For investors, patents can help protect market exclusivity for licensed products or partnerships and may increase the company’s strategic value in consumer healthcare and nicotine-replacement/personal care markets. The 8‑K also included a press release as an exhibit (Item 9.01).